We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

68 hedge funds and large institutions have $224M invested in Syros Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

380% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 5

178% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 9

39% more funds holding

Funds holding: 49 → 68 (+19)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

11% less capital invested

Capital invested by funds: $251M → $224M (-$26.8M)

Holders
68
Holders Change
+19
Holders Change %
+38.78%
% of All Funds
1.7%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
24
Increased
25
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.15M
3
CS
Candriam SCA
Luxembourg
+$2.26M
4
AIM
ARK Investment Management
Florida
+$2.2M
5
Millennium Management
Millennium Management
New York
+$2.13M

Top Sellers

Rank Fund Capital Flow
1
FP
Flagship Pioneering
Massachusetts
-$30.1M
2
RG
Redmile Group
California
-$6.24M
3
WMSA
Weiss Multi-Strategy Advisers
New York
-$386K
4
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$156K
5
GT
Glenmede Trust
Pennsylvania
-$148K
Name Holding Trade Value Shares
Change 		Change in
Stake
NI
26
Numeric Investors
Massachusetts
$807K +$1.03M +5,481 New
PP
27
PDT Partners
New York
$638K +$816K +4,337 New
Charles Schwab
28
Charles Schwab
California
$614K +$384K +2,041 +96%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$520K +$99.9K +531 +18%
Deutsche Bank
30
Deutsche Bank
Germany
$520K +$391K +2,081 +142%
TCIM
31
TIAA CREF Investment Management
New York
$471K -$45.1K -240 -7%
Morgan Stanley
32
Morgan Stanley
New York
$392K +$225K +1,198 +82%
WMSA
33
Weiss Multi-Strategy Advisers
New York
$368K -$386K -2,050 -45%
TA
34
Teachers Advisors
New York
$334K – – –
HLA
35
Hamilton Lane Advisors
Pennsylvania
$299K +$382K +2,031 New
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$290K -$47K -250 -11%
TI
37
Trexquant Investment
Connecticut
$282K +$360K +1,914 New
MWNA
38
Marshall Wace North America
New York
$259K +$324K +1,725 New
Wells Fargo
39
Wells Fargo
California
$253K +$58.7K +312 +22%
SOMRS
40
State of Michigan Retirement System
Michigan
$240K +$306K +1,628 New
GCP
41
GSA Capital Partners
United Kingdom
$240K +$307K +1,630 New
EMG
42
Ellington Management Group
Connecticut
$227K +$290K +1,540 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$197K – – –
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$187K +$7.71K +41 +3%
Two Sigma Investments
45
Two Sigma Investments
New York
$173K +$221K +1,176 New
CS
46
Credit Suisse
Switzerland
$154K +$198K +1,051 New
CSS
47
Cubist Systematic Strategies
Connecticut
$149K +$191K +1,013 New
Russell Investments Group
48
Russell Investments Group
United Kingdom
$133K +$170K +903 New
AIG
49
American International Group
New York
$123K +$11.8K +63 +8%
TRCT
50
Tower Research Capital (TRC)
New York
$118K +$152K +806 New
1
2
3

SYRS Hedge Fund Activity: Q3 2017 in Review

68 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2017, worth a combined $224M — down 11% from $251M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SYRS positions and 5 closed out — a net gain of 19 holders — while 25 added to existing stakes and 9 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $5.8M. The largest seller was Flagship Pioneering, cutting an estimated $30.1M.

  • 68 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2017, up from 49 in Q2 2017.
  • Funds reported $224M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2017, down 11% quarter-over-quarter.
  • 24 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 5 closed out, a net change of +19 holders.
  • The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was T. Rowe Price Associates, an estimated $5.8M added.
  • The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2017 was Flagship Pioneering, an estimated $30.1M sold.

Based on aggregated 13F filings for Q3 2017.